ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
256 W Beech St P.O. Box 32 Harrison, Michigan, USA 48625
(989) 424-9929
austin@clippershipsandcaravans.com
Copyright © 2023 roenews2. All Rights Reserved
